The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1, first-in-human, open-label, dose-escalation and -expansion study of gamitrinib, a first-in-class, mitochondria-directed inhibitor of the molecular chaperone heat shock protein-90 (Hsp90) in patients with advanced cancer.
 
Anthony Olszanski
Consulting or Advisory Role - Anaveon; Bristol-Myers Squibb; IO Biotech; Replimune; Signatera
Research Funding - Anaveon (Inst); Antengene (Inst); Clasp (Inst); Clasp (Inst); GlaxoSmithKline (Inst); Immatics (Inst); Lantern Pharma (Inst); Lilly (Inst); Normunity (Inst); Regeneron (Inst); Replimune (Inst); Shionogi (Inst); Solve (Inst); Tagworks (Inst); Takeda (Inst); Viewpoint Molecular Targeting (Inst)
 
Jessica Bauman
Consulting or Advisory Role - AVEO; Delcath Systems (I); Innovent Biologics; J & J; Merus; Pfizer
Travel, Accommodations, Expenses - Delcath Systems (I); Merus
 
Hannah Kinder
No Relationships to Disclose
 
Margaret von Mehren
Honoraria - Boehringer Ingelheim; Deciphera; Von Pfeffel Corporation
Consulting or Advisory Role - deciphera; Von Pfeffel Pharma
Research Funding - ASCO (Inst); Cogent Biosciences (Inst); Deciphera (Inst); IDRx (Inst); Novartis (Inst); Sumitomo Pharma Oncology (Inst); Theseus (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; deciphera
Other Relationship - NCCN
 
Teresa Lee
No Relationships to Disclose
 
Hossein Borghaei
Stock and Other Ownership Interests - Nucleai; Rgenix
Honoraria - Amgen; Axiom Biotechnologies; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Janssen Oncology; Jazz Pharmaceuticals; Pfizer; Regeneron; Regeneron
Consulting or Advisory Role - Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Beigene; BerGenBio; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Genentech; Genmab; Gilead Sciences; Grid Therapeutics; IO Biotech; ITeos Therapeutics; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merck; Mirati Therapeutics; Novartis; Novocure; Pfizer; PharmaMar; Puma Biotechnology; RAPT Therapeutics; Regeneron; Rgenix; Summit Therapeutics; Systimmune; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; EMD Serono; Genentech; Jazz Pharmaceuticals; Merck; Mirati Therapeutics; Novartis; Regeneron
Other Relationship - Incyte; Novartis; SpringWorks Therapeutics; Takeda; University of Pennsylvania
 
Namrata Vijayvergia
Honoraria - Guidepoint Global
Consulting or Advisory Role - Boehringer Ingelheim; Exelixis; Gilead Sciences; Jazz Pharmaceuticals; Pfizer; RayzeBio
Research Funding - Bristol-Myers Squibb/Medarex (Inst); ITM Isotope Technologies Munich (Inst); Oryzon Genomics (Inst); Puma Biotechnology (Inst); Zymeworks (Inst)
 
Michael Hall
Consulting or Advisory Role - Incyte; LynSight
Patents, Royalties, Other Intellectual Property - I share a patent with several Fox Chase investigators for a novel method to investigate hereditary CRC genes (Inst)
Other Relationship - Caris Life Sciences; Invitae; Myriad Genetics
 
Khushbukhat Khan
No Relationships to Disclose
 
Umar Hayat
No Relationships to Disclose
 
Dario Altieri
Patents, Royalties, Other Intellectual Property - I am a named inventor on the following patent: Patent #2,699,794 Title: Mitochondria-Targeted Anti-Tumor Agents Issue date: 7/19/2016 (Inst)